Epax launched EPAX® Evolve 05, the world’s first commercially available VLC-PUFA (very long chain polyunsaturated fatty acids) product, ahead of Vitafoods Europe.

VLC-PUFAs, a family of Omega-3 fatty acids, were recognized for their potential in healthy ageing. Pre-clinical studies indicated that supplementation with VLC-PUFAs was associated with improved sight[1], and that depletion was linked to age-related phenomena such as reduced bone density and muscle strength[2]. Further research suggested profound effects on skin health and male fertility.

Epax had been a leader in VLC-PUFA research derived from fish oil, discovering a method to concentrate these fatty acids from fish oil about ten years prior. The company held several patents in this field, paving the way for the development of EPAX® Evolve 05—a unique marine concentrate and the first of its kind available commercially.

Containing around ten times the VLC-PUFA content of crude fish oil, the product was part of the NovusLipid range, which featured innovative marine ingredients. Regulatory evaluations had confirmed that EPAX® Evolve 05 was not classified as a Novel Food, allowing it to be marketed in the EU following an assessment by the Norwegian Food Safety Authority on behalf of EFSA. In the US, Epax obtained self-affirmed GRAS status after peer-reviewed genotoxicity and repeat-dose toxicology studies[3],[4], supporting its safety profile.

The launch enabled Epax to provide researchers with samples for intervention studies, supporting further exploration of VLC-PUFA benefits.

Bjørn Refsum, CEO of Epax, commented at the time: “VLC-PUFAs offer enormous potential in areas like vision and healthy ageing. However, research into their benefits was previously hindered by a lack of material containing VLC-fatty acids in significant amounts. We’re proud to have developed a VLC-concentrate that opens the door for further research and introduces a new family of valuable fatty acids to the marketplace. The stage was set for a new era for Omega-3.”